Navigation Links
New class of RNA molecules may be important in human cancer
Date:9/11/2007

COLUMBUS, Ohio Research here shows that an obscure form of RNA, part of the protein-making machinery in all cells, might play an important role in human cancer.

These ultraconserved non-coding RNAs (UCRs) have been considered junk by some researchers, but a new report in the September issue of the journal Cancer Cell indicates that this may not be the case.

The study found that UCRs, like classic oncogenes, can contribute to cancer development. It also showed that the type and amount of UCRs is different in cancer cells for each of three cancer types, suggesting that these molecules might prove useful in diagnosing the disease and in determining a patients prognosis and perhaps even treatment.

Along with oncogenes, tumor suppressor genes and microRNA, this seems to be another family of genes that plays an important role in cancer, says principal investigator Carlo M. Croce, professor and chair of the department of molecular virology, immunology and medical genetics at Ohio State University and a researcher with Ohio States Comprehensive Cancer Center.

Our next step is to learn how they work and if they are good targets for drug therapy.

The new study involved a number of experiments. One showed that some genes that encode for UCRs are located in chromosome regions that are often lost or damaged in cancer cells. This suggests that certain UCRs might be genetic markers for cancer susceptibility.

In another experiment, Croce and his colleagues measured the activity of UCR genes in human chronic lymphocytic leukemia, and colorectal and liver cancer. Overall, they examined 133 tumor samples and 40 samples of corresponding normal tissue.

Each cancer type showed a specific activity pattern for certain UCRs, suggesting that these molecules might one day help distinguish between different types of human cancers.

Moreover, the investigators identified a signature of five UCRs able to differentiate a slowly progressing form of chronic lymphocytic leukemia and a form that progresses quickly and aggressively.

At the same time, they discovered that some of these UCRs might be regulated by microRNAs. This finding was particularly intriguing because it suggests a totally new regulatory mechanism that involves noncoding RNAs, Croce says.

Finally, this study showed that artificially lowering the level of one UCR in colon cancer cells caused many of them to die, reducing their spread by almost half and showing that UCRs can serve as oncogenes.

Overall, our findings indicate that these molecules are involved in cancer, Croce says. But we need to learn if they are also involved in other diseases such as Alzheimers and heart disease.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. “ Economy Class Syndrome
2. Latest Tumor Classification More Informative
3. Ultrasound may mean end to classic stethoscope
4. Self-Applied Acupressure May Reduce Sleepiness And Increase Alertness During Class Hours
5. Madhya Pradesh Cops to attend Yoga classes to reduce stress and weight
6. Sunflowers Could Hold the Key to New Class of AIDS Drugs
7. Campaigners Say No To Cannabis Reclassification
8. Kolkata To Get World-Class Cancer Hospital Soon
9. Peer Rejection Leads To Reduced Participation In Classroom Activities
10. East London Receives World Class New Private Hospital Facility
11. Welcome to ‘Stand Only’ Classrooms That Exercise The Brain And The Bod!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
(Date:4/25/2017)... Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is ... the treatment of acute or chronic problems, I focus on preventative care with all my ... If you have any questions, always feel free to contact my office and my trained ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement ... quarterback position. The former overall number one pick in the 2001 NFL Draft, to ... holds the record for the most career rushing yards by a quarterback (6,109) and ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... SAN DIEGO , April 18, 2017  Astute ... previewed a case series to be presented at the ... , which begins today and continues through April 22. ... and IGFBP-7 , used to assess risk for acute ... acute decompensated heart failure (ADHF). Elevated ...
Breaking Medicine Technology: